Trial Profile
Objective Measurement of Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With a Vascular Endothelial Growth Factor Inhibitor.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Central retinal vein occlusion
- Focus Therapeutic Use
- 14 Dec 2015 New trial record